Entering text into the input field will update the search result below

BridgeBio posts early results from mid-stage encaleret genetic disorder study

  • BridgeBio Pharma (NASDAQ:BBIO) posts early results from an ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), a rare genetic disorder.
  • In the study, participants received sequential, increasing daily doses of encaleret starting at

Recommended For You

More Trending News

About BBIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BBIO--
BridgeBio Pharma, Inc.